David Sommerhalder

7PUBLICATIONS
80CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Mar 14, 2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.

Yuxiang Ma, Yunpeng Yang, Yan Huang

|Aug 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Christopher T Chen, Vishesh Khanna, Shivaani Kummar

|Jun 01, 2024
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.

Toru Mukohara, Yeon Hee Park, David Sommerhalder

|Dec 12, 2017
Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review.

David Sommerhalder, Amol M Takalkar, Rodney Shackelford

Pageof 2

Frequent Collaborators

3 joint publications

Erika Hamilton

2 joint publications

Yeon Hee Park

2 joint publications

Kan Yonemori

2 joint publications

Toshinari Yamashita